Status:
ACTIVE_NOT_RECRUITING
ALICIA (Acalabrutinib in CLL Therapy)
Lead Sponsor:
AstraZeneca
Conditions:
Chronic Lymphocytic Leukemia
Eligibility:
All Genders
18+ years
Brief Summary
This is a multicenter non-interventional observational study conducted with a single hand arm to collect real-world data. In this study, commercially available acalabrutinib will be used as prescribed...
Eligibility Criteria
Inclusion
- Age ≥18 years
- Confirmed diagnosis of CLL
- Patient started treatment with monotherapy acalabrutinib (prescribed by physician decision no more than 4 weeks ago before screening)
- Capability of providing written Informed Consent Form
Exclusion
- Patients not corresponded to inclusion criteria
- Pregnancy
- Lactation
- Patients included in open-label trials
- Previous Bruton tyrosine kinase inhibitors (BTKI) treatment
Key Trial Info
Start Date :
February 3 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 28 2026
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT04746950
Start Date
February 3 2021
End Date
February 28 2026
Last Update
December 8 2025
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Ufa, Bashkortostan Republic, Russia, 450054
2
Research Site
Kaliningrad, Kaliningrad Oblast, Russia
3
Research Site
Khabarovsk, Khabarovskiy Kray, Russia, 680009
4
Research Site
Syktyvkar, Komi, Russia